Director/PDMR Shareholding
Primary Health Properties PLC
("PHP" or the “Company”),
Director/PDMR Shareholding
Primary Health Properties PLC
Director Dealings - LTIP
Primary Health Properties PLC, announces that the Remuneration Committee has approved the following awards of nil-cost options under the Company’s 2021 Long-term Incentive Plan (“LTIP”) to Directors as follows:
|
Director |
Number of shares under option |
|
Mark Davies |
1,400,871 |
|
Richard Howell |
857,843 |
The number of nil-cost options were calculated by reference to a price of £0.9180, being the average of the closing middle market quotations for the Company’s ordinary shares on 22, 23 and 26 October 2026.
The nil-cost options will vest subject to the attainment of performance conditions measured over three years to 31 December 2028. The remuneration committee has the discretion to adjust the awards downwards at vesting for malus reasons. Details of the operation of the LTIP are set out in the Company’s 2025 Report and Accounts.
Details of the transactions referenced above are included below in accordance with the under Article 19 of the retained EU law version of the Market Abuse Regulation (Regulation 596/2014).
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
(a) |
Name |
Mark Davies
|
|
|
2 |
Reason for notification |
||
|
(a) |
Position/Status |
Chief Executive Officer |
|
|
(b) |
Initial notification/amendment |
Initial notification
|
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||
|
(a) |
Name
|
Primary Health Properties PLC |
|
|
(b) |
LEI |
213800Y5CJHXOATK7X11
|
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date: and (iv) each place where transactions have been conducted |
||
|
(a) |
Description of the financial instrument, type of instrument and identification code |
Ordinary shares of 12.5p ISIN: GB00BYRJ5J14 |
|
|
(b) |
Nature of transaction |
Award of nil-cost options over the Company’s ordinary shares
|
|
|
(c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil cost |
1,400,871
|
||
|
(d) |
Aggregated Information |
Single transaction: N/A
|
|
|
(e) |
Date of transaction |
27 October 2026 |
|
|
(f) |
Place of transaction |
N/A
|
|
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
(a) |
Name |
Richard Howell
|
|
|
2 |
Reason for notification |
||
|
(a) |
Position/Status |
Chief Financial Officer |
|
|
(b) |
Initial notification/amendment |
Initial notification
|
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||
|
(a) |
Name
|
Primary Health Properties PLC |
|
|
(b) |
LEI |
213800Y5CJHXOATK7X11
|
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date: and (iv) each place where transactions have been conducted |
||
|
(a) |
Description of the financial instrument, type of instrument and identification code |
Ordinary shares of 12.5p ISIN: GB00BYRJ5J14 |
|
|
(b) |
Nature of transaction |
Award of nil-cost options over the Company’s ordinary shares
|
|
|
(c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Nil cost |
857,843
|
||
|
(d) |
Aggregated Information |
Single transaction: N/A
|
|
|
(e) |
Date of transaction |
27 October 2026
|
|
|
(f) |
Place of transaction |
N/A
|
|
For further information
Mark Davies CEO Richard Howell CFO
Primary Health Properties PLC Primary Health Properties PLC
David Purcell Investor Relations
Primary Health Properties PLC
T: +44 (0) 7921 190 136
E: david.purcell@phpgroup.co.uk
Sodali & Co Financial PR
Elly Williamson/Madeleine Gordon-Foxwell
T: +44 (0) 207 250 1446
E: PHP@client.sodali.com
Legal Entity Identifier: 213800Y5CJHXOATK7X11
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE